In a move that may come as a surprise to few in the med-tech space, the U.S. Centers for Medicare & Medicaid Services has proposed to offer coverage with evidence development (CED) for leadless pacemakers, the newest technology in cardiac electrophysiology. Medtronic would seem to still have the lead in the leadless pacemaker business not only because the FDA has approved no other such devices, but also because the company's FDA-mandated post-approval study appears to be well suited to fulfill the requirements for a CED study.